Theophylline


Generic Medicine Info
Indications and Dosage
Intravenous
Acute severe bronchospasm
Adult: Individualise dosing based on serum theophylline levels; use ideal body weight to calculate dose. As an adjunct to inhaled β2-selective agonists and systemic corticosteroids: In patients who have not received theophylline or other xanthine-containing medications in the past 24 hours: Loading dose: 4.6 mg/kg via IV infusion over 30 minutes. Maintenance dose: 0.4 mg/kg/hour. Max: 900 mg daily (unless serum levels indicate a need for larger dose). Dosing recommendations are designed to achieve approx 10 mcg/mL serum levels. In patients who have received theophylline or other xanthine-containing medications, serum theophylline concentration must be measured to determine a loading dose. Recommendations may vary among countries (refer to local or specific product guidelines).
Elderly: Individualise dosing based on serum theophylline levels; use ideal body weight to calculate dose. In patients who have not had theophylline or other xanthine-containing medications in the past 24 hours: Loading dose: 4.6 mg/kg via IV infusion over 30 minutes. Maintenance dose: 0.3 mg/kg/hour. Max: 400 mg daily (unless serum concentrations indicate a need for larger dose). Dosing recommendations are designed to achieve approx 10 mcg/mL serum levels.
Child: Individualise dosing based on serum theophylline levels; use ideal body weight to calculate dose. In patients who have not had theophylline or other xanthine-containing medications in the past 24 hours: Loading dose: 4.6 mg/kg via IV infusion over 30 minutes. Maintenance dose: Infants 4-6 weeks 1.5 mg/kg 12 hourly; 6-52 weeks Calculate dose based on the equation: Dose (mg/kg/hour) = (0.008 x age in weeks) + 0.21; Children 1-<9 years 0.8 mg/kg/hour; 9-<12 years 0.7 mg/kg/hour; 12-<16 years 0.5 mg/kg/hour (Max: 900 mg daily, unless serum theophylline levels indicate a need for larger dose); ≥16 years Same as adult dose. Dosing recommendations are designed to achieve approx 10 mcg/mL serum levels. In patients who have received theophylline or other xanthine-containing medications, serum theophylline concentration must be measured to determine a loading dose. Recommendations may vary among countries (refer to local or specific product guidelines).

Oral
Acute bronchospasm
Adult: Individualise dosing based on serum theophylline levels; use ideal body weight to calculate dose. As temporary measure if inhaled or parenteral β2-adrenergic agonist is not available for patients who have not received theophylline or other xanthine-containing medications in the past 24 hours: As conventional oral solution: Loading dose: 5 mg/kg as a single dose, to produce an average of 10 mcg/mL peak serum theophylline concentration. Recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Elderly: Dose reduction may be required.
Child: Loading dose: Same as adult dose.

Oral
Chronic bronchospasm
Adult: Individualise dosing based on serum theophylline levels. For treatment and prophylaxis of reversible bronchospasm associated with chronic asthma and other chronic lung diseases (e.g. chronic bronchitis, emphysema): As conventional oral solution: Initially, 300 mg daily in divided doses 6-8 hourly; after 3 days, if tolerated, may increase to 400 mg daily in divided doses 6-8 hourly; and then after 3 more days, if needed and tolerated, may increase to 600 mg daily in divided doses 6-8 hourly. As modified-release tab: Initially, 200-300 mg 12 hourly, may be increased by 50-100 mg 12 hourly with intervals of 3 days until satisfactory response is achieved or toxicity occurs. For modified-release preparations given once daily, usual doses are 400 mg or 600 mg once daily. Dosage recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Elderly: Dose reduction may be required.
Child: Individualise dosing based on serum theophylline levels; use ideal body weight to calculate dose. For treatment and prophylaxis of reversible bronchospasm associated with chronic asthma and other chronic lung diseases (e.g. chronic bronchitis, emphysema): As conventional oral solution: Infants Calculate dose based on the equation: Total daily dose (mg/day) = [(0.2 x age in weeks) + 5] x (weight in kg). Dosing interval depends on age: ≤26 weeks Divide into 3 equal doses administered at 8-hour intervals; >26 weeks Divide into 4 equal doses administered at 6-hour intervals. Children 1-15 years weighing ≤45 kg: Initially, 12-14 mg/kg daily in divided doses 4-6 hourly (Max: 300 mg daily); after 3 days, if tolerated, may increase to 16 mg/kg daily in divided doses 4-6 hourly (Max: 400 mg daily); after 3 more days, if needed and tolerated, may increase to 20 mg/kg daily in divided doses 4-6 hourly (Max: 600 mg daily); >45 kg: Same as adult dose. As modified-release tab: Up to 10 mg/kg 12 hourly. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Special Patient Group
Intravenous:
Patients with cardiac decompensation, cor pulmonale, sepsis with multi-organ failure, or shock: Maintenance dose: 0.2 mg/kg/hour. Max: 400 mg daily (unless serum theophylline levels indicate a need for larger dose).
Hepatic Impairment
Oral:
Dose reduction may be required.

Intravenous:
Maintenance dose: 0.2 mg/kg/hour. Max: 400 mg daily (unless serum theophylline levels indicate a need for larger dose).
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort. Some individual prep must be taken w/ meals or on an empty stomach. Refer to monographs for individual formulations.
Special Precautions
Patient with cardiac arrhythmia (excluding bradyarrhythmia), cardiomyopathy, CAD, CHF, unstable angina, severe hypertension; acute pulmonary oedema, cor pulmonale, COPD with acute exacerbations, cystic fibrosis, pneumonia, severe hypoxaemia; hyperthyroidism or hypothyroidism; active peptic ulcer; seizure disorder; acute febrile illness, viral infection, sepsis with multiorgan failure, shock, porphyria. Absorption of modified-release preparations may vary between brands and may not be interchangeable; refer to specific product guidelines. Avoid concomitant use with other xanthine agents. Smoking (including cessation) and alcohol consumption. Renal (in infants aged <3 months) and hepatic impairment (e.g. cholestasis, acute hepatitis, cirrhosis). Neonates, children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: May exacerbate cardiac arrhythmias; seizures; may exacerbate peptic ulcer; risk of urinary retention (particularly in elderly males with pre-existing partial urinary tract obstruction).
Cardiac disorders: Palpitations, tachycardia.
Endocrine disorders: SIADH (high dose).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, gastric irritation, GERD, haematemesis.
Immune system disorders: Hypersensitivity, anaphylactic or anaphylactoid reaction.
Metabolism and nutrition disorders: Anorexia, hyperuricaemia, hypokalaemia, hyperglycaemia.
Nervous system disorders: Headache, tremor, dizziness.
Psychiatric disorders: Insomnia, irritability, restlessness, reflex hyperexcitability, hyperactivity (in children), anxiety, agitation, sleep disorder.
Renal and urinary disorders: Diuresis (transient), albuminuria, haematuria.
Respiratory, thoracic and mediastinal disorders: Tachypnoea.
Skin and subcutaneous tissue disorders: Rash, alopecia.
Vascular disorders: Flushing, hypotension.
IV/Parenteral/PO: C
Monitoring Parameters
Monitor serum theophylline concentration (after treatment initiation, before dose increases; when new illness, worsening of chronic illness or changes in treatment regimen occur that may affect theophylline clearance, or in presence of signs or symptoms of toxicity); heart rate, respiratory rate; arterial or capillary blood gases (if necessary); fluid balance, acid-base balance, and electrolyte concentrations (during prolonged IV treatment). Assess for signs and symptoms of CNS effects (e.g. insomnia, irritability).
Overdosage
Symptoms: Nausea, vomiting (often severe), diarrhoea, anorexia, headache, insomnia, mild excitement or irritability, restlessness, tachycardia, hypertonia, exaggerated limb reflexes, hypotension, hypokalaemia, hyperglycaemia, hypomagnesaemia, metabolic acidosis, rhabdomyolysis, fever, extreme thirst, tinnitus, palpitations, arrhythmias, tremors, delirium, muscle twitching, severe dehydration, albuminuria, haematemesis, hyperthermia, profuse diaphoresis, seizures, stupor, and coma (in very severe cases). Management: Supportive and symptomatic treatment. Perform gastric lavage or administer activated charcoal within 1-2 hours of ingestion. In patients who are comatose, having seizures, or lack gag reflex, perform gastric lavage if an endotracheal tube with cuff inflated is in place. For patients with seizures, prioritise the establishment and maintenance of an adequate airway and then administer oxygen; administer IV diazepam to control seizures, some recommend using barbiturates or anaesthetics. Restore fluid and electrolyte balance. Measure plasma theophylline levels immediately upon presentation and at regular intervals. Administer antiemetics (e.g. ondansetron, metoclopramide) to treat vomiting. Monitor ECG; serum electrolytes and glucose (upon presentation and as clinically indicated). In severe cases of tachycardia, β-blockers may be given in non-asthmatic patients. Use of extracorporeal removal methods (e.g. charcoal haemoperfusion, haemodialysis) may be considered, but the risks of the procedure must be weighed against the potential benefits. Refer to local guidelines for specific recommendations.
Drug Interactions
Increased serum concentration with cimetidine, high-dose allopurinol (≥600 mg daily), disulfiram, interferon alfa, macrolide antibiotics (e.g. clarithromycin, erythromycin, troleandomycin), oral contraceptives, certain quinolones (e.g. enoxacin, ciprofloxacin), methotrexate, propranolol, tiabendazole, verapamil, viloxazine, mexiletine, isoniazid, fluvoxamine, tacrine and fluconazole. Reduced serum concentration with barbiturates, carbamazepine, phenytoin, ritonavir, sulfinpyrazone, aminoglutethimide, isoprenaline, and rifampicin. May enhance the urinary clearance of lithium. May increase the sensitivity and toxic potential of cardiac glycosides. May exhibit synergistic toxicity with ephedrine and other sympathomimetics. Concomitant use with ketamine may lead to reduced seizure threshold. Increased risk of ventricular arrhythmias with halothane. May potentiate the hypokalaemic effect of β2-agonists, corticosteroids, and diuretics. May inhibit the effect of adenosine receptor agonists (e.g. adenosine, regadenoson).
Food Interaction
May delay the rate of absorption with food. Increased clearance with low carbohydrate/high protein diet and daily consumption of charcoal-broiled beef. Plasma level may be reduced by St. John's wort. Decreased clearance with alcohol.
Lab Interference
May transiently reduce triiodothyronine. May increase levels of plasma glucose, free fatty acids, total cholesterol, HDL, HDL/LDL ratio, uric acid, and urinary free cortisol excretion. Beverages containing xanthine (e.g. coffee, tea, cocoa, cola) may interfere with certain serum theophylline tests.
Action
Description:
Mechanism of Action: Theophylline is a xanthine derivative with 2 distinct actions in the airways; smooth muscle relaxation (bronchodilation) and inhibition of airway response to stimuli (non-bronchodilator prophylactic effects). The mechanism of action has not been fully established; however, it is suggested that its bronchodilation action is mediated by competitive inhibition of phosphodiesterase, which increases intracellular cAMP. It enhances Ca uptake through adenosine-mediated channels leading to an increase in the force of diaphragmatic muscle contraction.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Food may decrease the rate of absorption. Time to peak plasma concentration: 1-2 hours (oral solution); within 30 minutes (IV).
Distribution: Rapidly distributed throughout extracellular fluids and tissues in the body. Crosses the placenta and enters breast milk. Volume of distribution: Approx 0.45 L/kg (range: 0.3-0.7 L/kg). Plasma protein binding: Approx 40-60%, mainly to albumin.
Metabolism: Metabolised in the liver via demethylation by CYP1A2 isoenzyme into 3-methylxanthine (active) and 1-methylxanthine, and via hydroxylation by CYP2E1 and CYP3A3 isoenzymes into 1,3-dimethyluric acid; 1-methylxanthine undergoes further hydroxylation by xanthine oxidase to 1-methyluric acid.
Excretion: Via urine (approx 10% as unchanged drug); faeces (small amounts as unchanged drug). Elimination half-life: 8.7 hours (range: 6.1-12.8 hours).
Chemical Structure

Chemical Structure Image
Theophylline

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2153, Theophylline. https://pubchem.ncbi.nlm.nih.gov/compound/Theophylline. Accessed May 31, 2024.

Storage
Tab/Oral solution: Store between 15-30°C. IV inj: Store at 25°C. Protect from freezing. Avoid excessive heat.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03DA04 - theophylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway diseases.
References
AA-Theo LA Sustained-release Tablets 200 mg and 300 mg (Pharmaforte [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 12/01/2024.

Anon. Theophylline (Pediatric and Neonatal Lexi-Drugs). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/03/2024.

Anon. Theophylline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/01/2024.

Anon. Theophyllines. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 12/01/2024.

Buckingham R (ed). Theophylline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/01/2024.

Joint Formulary Committee. Theophylline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/01/2024.

Nuelin 125 mg and 250 mg Sustained-release Tablet (iNova Pharmaceuticals Philippines Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/01/2024.

Theophylline Anhydrous and Dextrose Injection, Solution (B. Braun Medical Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Theophylline Solution (PAI Holdings, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Theophylline Tablet, Extended Release (Rhodes Pharmaceuticals L.P.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Theophylline Tablet, Extended Release (Teva Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Theophylline, Aminophylline. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 21/03/2024.

Uniphyllin Continus 200 mg Prolonged Release Tablets (Ennogen Healthcare Ltd). MHRA. https://products.mhra.gov.uk. Accessed 21/03/2024.

Disclaimer: This information is independently developed by MIMS based on Theophylline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • CP-Theo-50/CP-Theo-100
  • Slow-Theo SR
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in